Avibactam/aztreonam - AbbVie/AstraZeneca/Pfizer
Alternative Names: EMBLAVEO; ATM-AVI; Aztreonam-avibactam; PF-06947387Latest Information Update: 17 Oct 2025
At a glance
- Originator AstraZeneca
- Developer AbbVie; AstraZeneca; Biomedical Advanced Research and Development Authority; Innovative Medicines Initiative; Pfizer
- Class Amides; Anti-infectives; Antibacterials; Heterocyclic bicyclo compounds; Monobactams; Small molecules; Sulfates
- Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Gram-negative infections; Intra-abdominal infections; Nosocomial pneumonia; Urinary tract infections
Most Recent Events
- 28 May 2025 Launched for Gram-negative infections in Denmark (IV)
- 28 May 2025 Launched for Gram-negative infections in Sweden (IV)
- 17 Mar 2025 Launched for Intra-abdominal infections (Combination therapy, Complicated) in USA (IV)